J
Jean-Jacques Body
Researcher at Université libre de Bruxelles
Publications - 397
Citations - 21506
Jean-Jacques Body is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Breast cancer & Zoledronic acid. The author has an hindex of 70, co-authored 384 publications receiving 19608 citations. Previous affiliations of Jean-Jacques Body include The Breast Cancer Research Foundation & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
Alison Stopeck,Allan Lipton,Jean-Jacques Body,Guenther G. Steger,Katia Tonkin,Richard De Boer,Mikhail Lichinitser,Yasuhiro Fujiwara,Denise A. Yardley,María Viniegra,Michelle Fan,Qi Jiang,Roger Dansey,Susie Jun,Ada Braun +14 more
TL;DR: With the convenience of a subcutaneous injection and no requirement for renal monitoring, denosumab represents a potential treatment option for patients with bone metastases.
Journal ArticleDOI
Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
Ian R. Reid,Jacques P. Brown,Peter Burckhardt,Zebulun D. Horowitz,P J Richardson,Ulrich Trechsel,A Widmer,Jean-Pierre Devogelaer,Jean-Marc Kaufman,Philippe Jaeger,Jean-Jacques Body,Maria Luisa Brandi,Johann Broell,Raffaele Di Micco,Andrea R. Genazzani,Dieter Felsenberg,Joachim Happ,Michael J. Hooper,Jochen Ittner,Georg Leb,Hans Mallmin,Timothy M. Murray,Sergio Ortolani,Alessandro Rubinacci,Maria Sääf,Göran Samsioe,Leon Verbruggen,Pierre J. Meunier +27 more
TL;DR: Zoledronic acid infusions given at intervals of up to one year produce effects on bone turnover and bone density as great as those achieved with daily oral dosing with bisphosphonates with proven efficacy against fractures, suggesting that an annual infusion of zoledronic Acid might be an effective treatment for postmenopausal osteoporosis.
Journal ArticleDOI
Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical Trials
Pierre Major,Alain Lortholary,J. Hon,E Abdi,Gordon B. Mills,H D Menssen,F Yunus,Richard Bell,Jean-Jacques Body,E Quebe-Fehling,John W. Seaman +10 more
TL;DR: Zoledronic acid is superior to pamidronate; 4 mg is the dose recommended for initial treatment of HCM and 8 mg for relapsed or refractory hypercalcemia.
Journal ArticleDOI
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
Jean-Jacques Body,Thierry Facon,Robert E. Coleman,Allan Lipton,Filip Geurs,Michelle Fan,Donna Holloway,Mark C. Peterson,Pirow Bekker +8 more
TL;DR: A single s.c. dose of denosumab given to patients with multiple myeloma or bone metastases from breast cancer was well tolerated and reduced bone resorption for at least 84 days, and the effect diminished progressively through follow-up.
Journal ArticleDOI
Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice.
Jean-Claude Souberbielle,Jean-Jacques Body,Joan M. Lappe,Mario Plebani,Yehuda Shoenfeld,Thomas J. Wang,Heike A. Bischoff-Ferrari,Etienne Cavalier,Peter R. Ebeling,Patrice Fardellone,Sara Gandini,Damien Gruson,Alain P. Guerin,Lene Heickendorff,Bruce W. Hollis,Sofia Ish-Shalom,Guillaume Jean,Philipp von Landenberg,Alvaro Largura,Tomas Olsson,Charles Pierrot-Deseilligny,Stefan Pilz,Angela Tincani,Andre Valcour,Armin Zittermann +24 more
TL;DR: An international expert panel formulated recommendations on vitamin D for clinical practice, taking into consideration the best evidence available based on published literature today, and reached substantial agreement about the need for vitamin D supplementation in specific groups of patients in these clinical areas.